Q-omics provides the consensus-scored BIVM-ERCC5 profile across patient tissues and cancer cell-line models. BIVM-ERCC5 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, BIVM-ERCC5 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, BIVM-ERCC5 RNA expression shows 8,672 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight COAD, KIRC, and KIRP as cancer lineages where BIVM-ERCC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BIVM-ERCC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BIVM-ERCC5 survival associations across molecular data types. BIVM-ERCC5 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BIVM-ERCC5 RNA expression–survival associations across cancer types. High BIVM-ERCC5 expression shows unfavorable associations in COAD, STAD, LUAD, THYM, SKCM and CESC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for BIVM-ERCC5 RNA expression.
This table summarizes BIVM-ERCC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for BIVM-ERCC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BIVM-ERCC5 shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, KIRP, CHOL and COAD. The KIRC box plot shows higher BIVM-ERCC5 RNA expression in tumor versus normal tissue (log2 FC = +0.043, t-test p < 0.001).
This table shows molecular features associated with BIVM-ERCC5 in patient tissues and cancer cell lines. In patient samples, BIVM-ERCC5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, BIVM-ERCC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
